Hello, everyone, and how are you today? We are doing just fine, thank you, despite the mugginess descending on the Pharmalot campus this morning. Our official mascot is settling down for a morning snooze and we are foraging for tidbits, which still feels like a game of catch up following our recent holiday break. Nonetheless, we are up to the task (thanks, in part, to a cup of stimulation — butter pecan, in this case). So here you go. As always, we hope you have a smashing day and conquer the world. And of course, do stay in touch. …
The Biotechnology Innovation Organization, the lobbying group that represents roughly 1,000 biotech companies, is wrestling with inner turmoil that threatens its ability to navigate a Washington that is eager to reform drug pricing, STAT reports. Five of its top lobbyists have left within the last eight months, including the executive who led policy and legal work for more than a decade. The tumult extends beyond the lobbying operation: An effort to talk about drug pricing policy last year inflamed existing tensions within the membership.
A Johnson & Johnson (JNJ) HIV vaccine using the same basic technology as the Covid-19 shot failed to prevent infection, dealing yet another blow to efforts to create a vaccine against the virus, STAT tells us. The study, which was launched in 2017 and called Imbokodo, enrolled 2,600 women in southern Africa who were at very high risk of HIV infection. The goal was not to completely prevent infection, but to reduce the chance of infection by half.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
